Clinical Trial: Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC

U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07134556) titled 'Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC' on Aug. 06.

Brief Summary: The ADJUNCT is a single-arm, phase II clinical trial to evaluate the safety and efficacy of the combination of zimberelimab, domvanalimab and sacituzumab govitecan as first-line therapy for patients with PD-L1 positive advanced or metastatic triple-negative breast cancer.

Study Start Date: Dec. 08, 2025

Study Type: INTERVENTIONAL

Condition: Triple Negative Breast Cancer PDL-1 Positive

Intervention: DRUG: Zimberelimab (AB122)

Pati...